[{"from": "human", "value": "Describe this molecule. [C][N][C][C][C@][C@@H1][C@H1][Branch2][Ring1][P][C][C][C@][Ring1][=Branch1][Branch2][Ring1][Branch2][C@H1][Ring1][#Branch2][C][C][=C][Ring1][#Branch2][C][=Branch1][#Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][O][Ring1][S][O][O][C][C][O][C][C][O][C][C][O][C][C][O][C][C][O][C][C][O][C]"}, {"from": "gpt", "value": "The molecule is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class. This is also thought to be the reason behind the reduced frequency of CNS-mediated adverse effects, like sedation, seen with Loxicodegol. Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain"}]